Electra Therapeutics, Inc. announced the pricing of its upsized initial public offering of 23,333,334 shares of common stock at $15.00 per share, for expected gross proceeds of approximately $350.0 million before underwriting discounts, commissions and estimated offering expenses. The South San Francisco-based late clinical-stage biopharmaceutical company has also granted the underwriters a 30-day option to purchase up to an additional 3,500,000 shares at the public offering price, less underwriting discounts and commissions, with all shares being offered by Electra. The shares are expected to begin trading on The Nasdaq Global Select Market on September 18, 2026 under the ticker symbol ETRA, and the offering is expected to close on September 21, 2026, subject to customary closing conditions. Jefferies, TD Cowen, Evercore ISI and Cantor are acting as joint book-running managers for the offering. Registration statements relating to the securities were filed with the U.S. Securities and Exchange Commission and became effective on September 17, 2026.
China Dvlp Bk Finl Leasing Co
Evercore Partners Inc
Jefferies Financial Group Inc